Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 5/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19738141 | 0.86 | NPC1 (0.56) | NPC1RAB9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL14168120 | 0.85 | NPC1 (0.57) | NPC1RAB9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL19734616 | 0.85 | NPC1 (0.57) | NPC1RAB9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL28344002 | 0.83 | NPC1 (0.56) | NPC1RAB9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL28344001 | 0.83 | NPC1 (0.56) | NPC1RAB9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL12738664 | 0.83 | NPC1 (0.55) | NPC1RAB9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL3861513 | 0.83 | CYP2C19 (0.58) | MEN1KMT2AGAAALDH1A1HTT | |
| SCHEMBL7048118 | 0.82 | NPC1 (0.54) | NPC1RAB9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL14167832 | 0.82 | MEN1 (0.54) | NPC1RAB9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL14167813 | 0.82 | NPC1 (0.51) | NPC1RAB9AHPGDSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745431-B2 | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof | VELA ACQUISITION CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1581206-A4 | TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES | VELA ACQUISITION CORP (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1567161-A4 | PHARMACEUTICAL COMPOSITION OF 1-(3,4-DIMETHOXYPHENYL)-4-METHYL-5-ETHYL-7-METHOXY-8-HYDROXY-5H-2,3-BENZODIAZEPINE AND USES THEREOF | VELA ACQUISITION CORP (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1567162-A4 | TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES | VELA ACQUISITION CORP (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2007-02-08 | — | — | US | disclosed |
| EP-1689408-A1 | TREATMENT OF INFLAMMATORY DISORDERS OF THE EPITHELIUM WITH LOW DOSE 2,3-BENZODIAZEPINES | Vela Pharmaceuticals Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7022700-B2 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1581206-A1 | TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES | Vela Pharmaceuticals Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1567161-A2 | PHARMACEUTICAL COMPOSITION OF 1-(3,4-DIMETHOXYPHENYL)-4-METHYL-5-ETHYL-7-METHOXY-8-HYDROXY-5H-2,3-BENZODIAZEPINE AND USES THEREOF | Vela Pharmaceuticals Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157833-A1 | Pharmaceutical composition of 1- (3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof | VELA PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040138209-A1 | Treatment of inflammatory disorders with 2,3- benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040138210-A1 | Method of increasing neutrophil production using 2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004050080-A1 | TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050616-A2 | TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050040-A2 | PHARMACEUTICAL COMPOSITION OF 1-(3,4-DIMETHOXYPHENYL)-4-METHYL-5-ETHYL-7-METHOXY-8-HYDROXY-5H-2,3-BENZODIAZEPINE AND USES THEREOF | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050615-A2 | METHOD OF INCREASING NEUTROPHIL PRODUCTION USING 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-6638928-B1 | Benzodiazepines administered for irritable bowel syndrome and nonulcer dyspepsia. | VELA PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138209-A1 | Treatment of inflammatory disorders with 2,3- benzodiazepines | LTB4R2, LTB4R, GABRA4 | NPC1 1240/4885RAB9A 3531/4885HPGD 689/4885 |
| US-20040157833-A1 | Pharmaceutical composition of 1- (3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof | GABRA4, GABBR1, GABRB2 | NPC1 941/4885RAB9A 2363/4885HPGD 857/4885 |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | LTB4R2, LTB4R, PTGER4 | NPC1 1480/4885RAB9A 2968/4885HPGD 548/4885 |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | OPRL1, OPRD1, GABRR1 | NPC1 844/4885RAB9A 1836/4885HPGD 213/4885 |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | GABBR2, GABBR1, GABRB3 | NPC1 1469/4885RAB9A 2984/4885HPGD 602/4885 |
| US-20040138210-A1 | Method of increasing neutrophil production using 2,3-benzodiazepines | GABRR1, GABRA1, GABRA3 | NPC1 904/4885RAB9A 2306/4885HPGD 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.